INTRODUCTION
The FDCs approved for treatment of T2DM in the USA (as well as the names of FDCs also available in Europe) are listed in Table 1 .
For most of these FDCs, bioavailability of each component drug is equivalent to that seen when coadministered as separate pills, as demonstrated for regulatory approval. [2] [3] [4] [5] [6] [7] [8] [9] With metformin/ glyburide, bioavailability of metformin is equivalent to that seen when coadministered with glyburide as separate pills; however, the area under the plasma concentration versus time curve for glyburide is higher than that seen when coadministered with metformin as separate pills. Using monotherapy to target a single defect is often inadequate to achieve glycemic goals, and the result is prolonged e x p o s u r e t o h y p e r g l y c e m i a a n d a n increased risk of diabetic complications.
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Consequently, combination therapy using C o m b i n a t i o n a n t i h y p e r g l y c e m i c pharmacotherapy will eventually be necessary for the majority of patients with T2DM, owing to the progressive nature of the disease. 15, 16 Furthermore, because these patients often have hypertension, dyslipidemia, and other comorbidities that require pharmacotherapy, 
USE OF FDCs IN T2DM
To date, 10 FDCs have been approved for use in the treatment of T2DM in the USA (Table 1) .
Despite their utility and convenience, FDCs 
ADDRESSING CONCERNS REGARDING THE USE OF FDCs FOR T2DM

Therapeutic Effectiveness
Therapeutic effectiveness with FDCs is generally equivalent to combination therapy with their component drugs given as separate pills.
As shown in Table 2 for patients with T2DM have revealed that a 10% poorer score on an adherence measure corresponds with a 0.14% increase in A1C. 34 Among patients with T2DM using combination therapy, adherence tends to be greater with FDCs than with separate pills 21, 31 and greater after switching from monotherapy to an FDC rather than to separate-pill combinations. 18, 19, 21 In the previously cited retrospective analysis by Thayer et al., adherence rates declined slightly among patients who were switched from monotherapy to combination therapy, but the decline was significantly smaller when switching to an FDC versus switching to separate-pill combinations. 20 In contrast, among patients who were already using separate-pill combinations, adherence improved significantly when switching to an FDC.
Treatment adherence tends to improve with drug regimens that are simplified by reducing the number of pills [41] [42] [43] and reducing dosing frequency. 44, 45 By definition, all FDCs result *Defined as symptoms and blood glucose ≤50 mg/dL in the studies of MET/GLY, GLIP/MET, MET/REPAG, and SAXA/ MET, as symptoms and/or blood glucose <60 mg/dL in the study of PIO/MET, and as "events" in the study of SITA/MET. †Prestudy dosage of MET maintained. Mean daily MET dose presented. ‡SAXA is not approved at 10 mg; Kombiglyze XR is available with SAXA 2.5 mg plus MET 1000 mg or with SAXA 5 mg plus MET 500 or 1000 mg. GLIM=glimepiride; GLIP=glipizide; GLY=glyburide; MET=metformin; NR=value not reported; PIO=pioglitazone; REPAG=repaglinide; ROSI=rosiglitazone; SAXA=saxagliptin; SITA=sitagliptin; XR=extended-release formulation. 
Cost-Effectiveness
The estimated total of direct and indirect costs of diabetes in the USA was $174 billion in 2007
(most recent data available). 46 In a systematic review, inadequate adherence to treatment for diabetes was linked to more healthcare utilization and higher costs (although the review also revealed wide methodologic variability among cost-effectiveness studies). 47 Conversely, improved adherence has been associated with lower costs in treating dyslipidemia. 38 R o c h e , s a n o f i -a v e n t i s , S a n t a r u s , a n d 
